Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin plus dendritic cell vaccination in stage III/IV melanoma
NL-OMON36238Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2011
- Modality
- Small Molecules, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of cisplatin and WT1/hTERT/Survivin-loaded dendritic cell vaccine in melanoma (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Immunogenicity and Feasibility. Started Feb 2011; status: active, not recruiting.
02
Drugs
cisplatinWT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON36238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36238.